Using Outcomes-Based Pricing for Medical Devices to Improve Cardiovascular Disease Treatment Value

2018-03-30T18:04:16+00:00 March 29th, 2018|Viewpoints|

In a post on the IVI-sponsored Health Affairs featured blog series Drugs and Medical Innovation, Daniel Blumenthal, Samuel Nussbaum (IVI Strategic Advisory Panel Chair), Mark Linthicum (IVI Director of Scientific Communications), and Neil Weissman (IVI Strategic Advisory Panel member) explore how outcomes-based pricing agreements (OBAs) could be utilized for medical devices used to treat cardiovascular disease to improve clinical and financial accountability among clinicians, insurers, and device makers.

Read the full article here.